Physician profile
Laura M Marks
NPI 1982770145
$2,496.96
in general payments reported to CMS, 2019-2025
19 companies · $603 in 2025
The $603 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $165 · 2021: $88.40 · 2022: $412 · 2023: $496 · 2024: $508 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $645.23 | 2022-2025 | Azstarys |
| Tris Pharma INC | $348.89 | 2019-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $241.74 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $222.62 | 2019-2025 | |
| Kaleo, INC. | $150.33 | 2019-2023 | Auvi-Q |
| Glaxosmithkline, LLC. | $146.16 | 2020-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $141.04 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $112.82 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $104.54 | 2021-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $76.68 | 2019-2022 | |
| Pfizer INC. | $72.47 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $67.44 | 2024-2025 | Koselugo |
| Avion Pharmaceuticals | $37.20 | 2023 | Methylphenidate Hydrochloride |
| Shire North American Group INC | $33.60 | 2019 | |
| Neos Therapeutics, LP | $26.16 | 2019-2023 | Adzenys Xr-Odt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $24.73 | 2024 | Relexxii |
| Avanir Pharmaceuticals, INC. | $18.22 | 2019 | |
| Verrica Pharmaceuticals INC. | $15.65 | 2023 | Ycanth |
| Phadia US INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.